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Methodology for Statistical Analysis of
SENCAR Mouse Skin Assay Data
by Judy A. Stober*
Various response measures and statistical methods appropriate for the analysis of data collected in the
SENCAR mouse skin assay are examined. The characteristics of the tumor response data do not readily
lend themselves to the classical methods for hypothesis testing. The advantages and limitations of con-
ventional methodsofanalysisandmethodsrecommended intheliterature arediscussed. Severalalternative
response measures that were developed specifically to answer the problems inherent in the data collected
in the SENCAR bioassay system are described. These measures take into account animal survival, tumor
multiplicity, and tumor regression. Statistical methods for the analysis of these measures to test for a
positive dose response and a dose-response relationship are discussed. Sample data from representative
initiation/promotion studies are used to compare the response measures and methods of analysis.
Introduction
The SENCAR mouse skin initiation/promotion bioas-
say has been widely used to test for chemical carcino-
gens and tumor initiators and promoters. A general
description of the SENCAR skin assay system and
mouse skin tumorigenesis can be found in Slaga et al.
(1) and Bull et al. (2). In general, the test substance is
administered to the animals, and the appearance ofskin
tumors (papillomas orcarcinomas) onindividual animals
is charted for a specified period of time. Compounds,
dose levels of a given compound, and/or routes of ex-
posure are then compared by evaluating the tumor in-
cidence among the treatment groups ofinterest. A pos-
itive association is defined as a reproducible increase in
the occurrence of tumors, and a negative association is
defined as the absence of such an increase.
Statistics provide the necessary procedures for sum-
marizing the relevant data and a mechanism for eval-
uating the strength of the association observed. As in
any experimental situation, appropriate statistical
methods are essential. The statistical analysis methods
shouldbe sensitive to the characteristics ofthe response
data. The multiplicity of tumors, as well as their time
of occurrence, can and should be used as indicators of
carcinogenicity. Unfortunately, the characteristics of
the SENCAR skinbioassay datado not lend themselves
readily to the classical techniques for data analysis. In
particular, early animal mortality and tumor regression
complicate the analysis.
The objective of this paper is to define appropriate,
sensitive, and useful statistical procedures foranalyzing
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data obtained from a SENCAR mouse skin assay. Sta-
tistical methods commonly used or recommended in the
literature will be reviewed. The advantages and dis-
advantages of each method will be discussed. Several
alternative methods developed for the SENCAR track-
ing system at the Health Effects Research Laboratory
ofthe U.S. Environmental Protection Agency (HERL/
EPA) will be presented and evaluated using repre-
sentative data sets.
Several general principles were used as guidelines in
examining and evaluating statistical methods for the
analysis of SENCAR skin tumor data. First, the ques-
tions investigated by the experiment should be ad-
dressed by the test procedure in a straight-forward
manner with sufficient power to detect biologically
meaningful differences. That is, the methodology se-
lected should minimize the rates of false positives and
false negatives. Second, the methods should be intui-
tively reasonable and sensitive to the characteristics of
the data, using all relevant information available. Fi-
nally, the assumptions for the statistical validity ofthe
method must be reasonably met, and the procedure
should be robust, whether it is an omnibus or a direc-
tional test.
Background
The SENCAR mouse skin assay can be designed to
investigate two separate but related hypotheses. The
first hypothesis asks: Is there evidence for an increase
in tumoroccurrence associated with the treatment (i.e.,
is there a positive dose response)? Ifthere is, then the
second hypothesis can be used to investigate evidence
for and may even be used to estimate a dose-response
relationship. The current work limits this investigationJ. A. STOBER
to a monotone response, thus the hypotheses can be
stated as: Is there an increase in tumor occurrence as-
sociated with an increase in dose of a compound? Ad-
ditionally, questions concerning the effect of exposure
route and tumorigenic potency can be addressed using
the same methods discussed below. The experimental
endpoints onwhich a statistical analysis is based include
animalbodyweight, foodandwaterconsumption, tumor
counts, and pathology reports. Although each of these
measurements supplies information on toxicity, this pa-
per will focus only on tumor count data and how to use
these data to calculate a reliable response measure for
toxicity.
Methods
Several studies have reported on the use of various
statistical methods to analyze mouse skin assay data (3-
6). The conventional approach to summarizingthe assay
results usually includes some or all of the following in-
formation: dose, number of animals exposed, and re-
sponse measures such as percentage of animals with
tumors, average (median) number ofweeks to first tu-
mor (±SD), time to first tumor observation, time to
last tumor observation, and number of tumors per an-
imal. The classical statistical methods (e.g., Student's
t-testandcontingencytableanalysis) arenotnecessarily
appropriate for these response measures. The selection
of a response measure and statistical methods for the
analysis of tumor data is complicated by certain char-
acteristics ofthe study data. Potential problems in the
analysis arise from animal mortality occurring before
the termination of the study, differences in survival
amongthetreatmentgroups, andtumorregression. For
example, analysis of tumor occurrence is complicated
byincomplete observations in animals due toearly mor-
tality, which may be directly related to the toxicity of
the compound. Tests that ignore these factors may re-
sult in a loss ofpower, that is, the ability to detect true
differences. If no early deaths occur, the data analysis
is decidedly easier. Ignoring early animal mortality and
examiningonlysurvivinganimals maylead to erroneous
results.
The percentage ofanimals with skin tumors at a spe-
cifictime hasbeentraditionally analyzedbyusingeither
Fisher's Exact Test for pairwise comparisons between
treatment groups or a chi-squared test. In addition,
linear, probit, and logit models have been used to fit
dose-response curves. Tumor counts observed at a spe-
cific time have been analyzed using various parametric
and nonparametric procedures. These procedures in-
clude Student's t-test, analysis of variance procedures,
linear regression, and log-linear models. Drinkwater
and Klotz(4)examined theanalysis oftumormultiplicity
data for surviving animals using the Student's t-test,
Wilcoxon's Rank Sum Test and a two-sample likelihood
ratio test based on the negative binominal distribution.
Both ofthese response measures, percentage ofanimals
with skin tumors and tumor count, ignore differential
survival and provide no information on the pattern of
tumor development. The parametric methods require
various assumptions to ensure their validity, and these
assumptions may not hold true.
The pattern of tumor development can be examined
by using the time to first tumor as the response mea-
sure. The time to first tumor is calculated as the time
from initial exposure to the appearance of the tumor.
Cumulative incidence curves can be estimated by using
various parametric procedures, e.g., Weibull (5) and
nonparametricmethods, e.g., Kaplan-Meier (3). The cu-
mulative incidence curves can be displayed graphically
and the estimated median time to first tumor reported
as a descriptive statistic. These methods include all an-
imals at risk, adjustingfordifferences inmortality rates
among the groups. They provide overall measures of
thecompound's effect oninitialtumordevelopment. The
entire incidence curve, rather than a single point in
time, can be statistically compared for differences
among treatment groups. This method is limited by the
fact that it ignores tumor multiplicity, and the median
time to first tumor cannot always be calculated directly
from the observed data. Additionally, the parametric
methods require the assumption of a specified model
distributionthatmay ormaynotbetestedfor"goodness
of fit."
The Toxicology and Microbiology Division of HERL/
EPA has developed and implemented atrackingsystem
for collecting data in the mouse skin assay system. In
addition to the daily observation of the animals for
health monitoring and morbidity, the animals are ob-
served weekly, and all grossly observed tumors are in-
dividually charted as to location, size, and type (papil-
loma or carcinoma). Only those tumors which are
observed for aminimum ofthree consecutive weeks are
included in the permanent and cumulative tumor count.
All individual tumors are charted weekly until they re-
gress or coalesce, or until the animal is sacrificed.
In developing the methodology to be used in the
analysis of tumor data from the tracking system, the
multiplicity oftumors and theirtime ofoccurrence were
used as indicators ofcarcinogenicity. The objective was
to define summary response measures and statistical
methods that would simultaneously take into account
survival rates and the total tumor occurrence pattern,
includingtumormultiplicity and regression. Crump and
Ng (7) developed several approaches for testing for a
dose-related effect and applied the methods to several
tracking system data sets. Table 1 lists the response
measures considered. The response is calculated over
the entire study time. A response measure is calculated
for each animal with its value censored at the time of
the animal's death. Tumors that appear at the same
location at nonoverlapping times are counted as single
tumors.
The univariate response measures admittedly have
inherent weaknesses. The time to first tumor is defined
as previously discussed. The totalnumberofpermanent
and cumulative tumors reflects tumor multiplicity, but
does not take the time of occurrence and duration into
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Table 1. Tumor response measures.
Measure Comments
Univariate
Time to first tumor Ignores multiplicity of tumors
Total number of Ignores time of tumor occurrence,
permanent tumors duration and tumor regression
Total number of Ignores time of tumor occurrence
cumulative tumors and duration
Integral with respect to Takes duration into account but
(w.r.t.) time of the ignores exact time of occurrence
number of tumors
Weighted sum of Each tumor weighted by its time
tumors of appearance. Ignores tumor
regression
Multivariate
Multiple times to tumor Takes multiple tumors per animal
into consideration
account. Theintegralwith respect totime ofthe number
of tumors is defined as follows.
Let ti < . . . < tk be the observation times. A tumor
seen at time ti, for i = 2, . .. , k- 1, contributes a factor
of (ti 1 - ti 1)/2 to the integral. A tumor seen at time
t1 and tk contributes a factor of(t2 - t1) and (tk - tk-1),




- tl) + ni(ti+ 1
- ti - 1)/2 + nk(tk tk- 1)
where ni is the number of tumors seen at time ti, for i
= 1, ..., k. The integral takes duration into account
but not the specific time of occurrence. The weighted
sum oftumors weights each tumor by the time from its
appearance until the end of the experiment.
Totestfor adose-response effectusingtheunivariate
response measures, both trend and multiple comparison
"survival"-type analysis tests were examined by Crump
and Ng. The multiple comparison test of Gehan and
Wilcoxon (8-10) was examined. It is an omnibus test,
in the sense that it has power to detect nearly all types
of differences. The trend test considered was a Cox-
type trend test discussed by Tarone (11). It is based on
the proportional hazard model and is a one-sided direc-
tional test. For the univariate tests, it was assumed
that the response measure, either the total number of
tumors or the integral with respect to time ofthe num-
ber of tumors, was censored at the value attained at
the time ofdeath or study termination. The test statis-
tics were calculated by using the PHGLM and SURV-
Table 2. Tumor multiplicity data from SENCAR mouse studies.a
Phorbol
No. of myristate Length of
No. of No. of animals acetate used study,
studies dose groups per group as promoter? weeks
8 2 40 Yes 31-36
10 3 40 Yes 52
6 4 40 Yes 52
'Only those tumors, both papillomas and carcinomas, observed for
3 consecutive weeks are included in tumor count.
Table 3. Gehan-Wilcoxon multiple comparison test vs. Cox-type
trend.
Response Total no. Percentage of data sets
measure of data sets GW S Coxd GW > Coxd
Time to first tumor
+/+
a 15 60 40
_b 8 63 37
+/_C 1 0 100
Integral w.r.t. time (week = 24)
+/+ 7 100 0
-/- 8 100 0
+/- 5 100 0
Integral w.r.t. time (week = last)
+I+ 8 75 25
-/- 9 89 11
+/- 7 100 0
Total no. permanent tumors (week = 24)
+/+ 7 100 0
-/- 9 89 11
+/- 4 100 0
Total no. permanent tumors (week = last)
+/+ 12 92 0
-/- 9 78 0
+/- 3 100 0
Total no. cumulative tumors (week = 24)
+/+ 7 100 0
-/- 8 100 0
+/- 5 100 0
Total no. cumulative tumors (week = last)
+/+ 7 86 14
-/- 9 89 11
+/- 4 100 0
aSignificant (p < 0.05) by both statistical methods of analysis.
bNonsignificant (p > 0.05) by both statistical methods of analysis.
'Significant by only one statistical method.
d Comparison based on test statistic p-value.
TEST procedures from the Statistical Analysis System
(SAS) (12). Themultivariateregressionanalysismethod
ofPrentice et al. (13) was used to examine the multiple
times to tumor data. It is a generalization of the Cox-
type trend test applied to the univariate data. The mul-
tivariate test statistic was calculated using a modified
version of the program R-COX developed at the Fred
Hutchison Cancer Research Center.
Analysis of SENCAR Tracking
System Data
SENCAR skin assay data collected on the tracking
system were analyzed using the methods developed.
The various response measures and statistical methods
were compared. Table 2 describes the studies included
in the present report. The evaluation included 24 data
sets from initiation/promotion studies that followed, in
general, the protocol procedure outlined in Bull et al.
(2). The univariate response measures were calculated
for two study duration times: 24 weeks and the entire
study period.
Results of the Gehan-Wilcoxon multiple comparison
test were compared to the Cox-type trend test for the
analyses oftheunivariate measures (Table3). Theprob-
ability level of the test statistic was the basis for com-
parison. Using an a level of 0.05, the data sets were
7J. A. STOBER





Time to first tumor vs.
Integral w.r.t. time 95 92
Total no. permanent tumors 90 92
Total no. cumulative tumors 95 90
Integral w.r.t. time vs.
Total no. permanent tumors 95 100
Total no. cumulative tumors 100 100
Total no. permanent tumors vs.
Total no. cumulative tumors 95 100
Multivariate
Agreed with univariate results in 8 of the 11 data sets analyzed.
Multivariate test found significant differences in 2 ofthe 3 analyses
for which there was disagreement.
aBased on Gehan-Wilcoxon test statistic: p-value S 0.05 vs. p-value
> 0.05.
categorized according to the agreement of the results
from the two test methods. For all response measures
and time periods, the Gehan-Wilcoxon test showed
greater power that the Cox-type trend test. The dif-
ference between the methods was less in the analysis
oftime to first tumor than in the integral or total tumor
count analyses. In every analysis of tumor count data
where the results differed between the two test meth-
ods, the Gehan-Wilcoxon test had a higher significance
level, probably because it tests for a wide range of al-
ternative hypotheses, whereas the trend test tests for
a monotone dose response.
The univariate response measures were compared
based on the significance level oftheir test statistic us-
ing the Gehan-Wilcoxon method (Table 4). An a level
of 0.05 was used as the cut-off point for significance.
For both the 24-weekdata analysis and the entire study
period analysis, the percent agreement between re-
sponse measures was at least 90%.
Eleven of the 24 data sets were analyzed by using
the multivariate stratified proportional hazard model of
Prentice et al. (13). In 8 of the 11 cases, the results
agreed with those of the univariate analysis. In two of
the three cases where there was disagreement, the mul-
tivariate test statistic showed a significant association
between dose of the compound and tumor occurrence.
The univariate methods of analysis for the tumor
count integral and total tumor count assume that an
animal's tumor observation is censored at its value at
the time ofdeath. This approach could possibly bias the
analysis and lead to erroneous results. With both meas-
ures, animals dying at different times with equal re-
sponses are treated equivalently. Intuitively, tumor-
free deaths occurring at the end ofthe study should be
considered greater evidence for a no-treatment effect
than tumor-free deaths occurring earlier in the study.
Similarly, a death occurring early in the study in an
animal with a specific tumor response should be consid-
ered greater evidence for a toxic effect than a death
occurring later in the study in an animal with the same
Table 5. Effect of early cut-off time.
Number of studies
Weekb
Response measure 24 28 32 >32 Total
Integral w.r.t. time
Significanta 11 3 1 3 18
Nonsignificant 3 - - 3 6
Total no. current tumors
Significant 10 4 1 2 17
Nonsignificant 3 - - 4 7
Total no. cumulative tumors
Significant 9 4 - - 13
Nonsignificant 3 - - 4 7
ap S 0.05, Gehan-Wilcoxon Multiple Comparison Test.
bEarliest week minimum p-value obtained (i.e., maximum differ-
ence observed).
tumorresponse. To examine the effect ofmortality, the
study time periods for data analysis were varied. The
maximum difference (minimum test statisticp-value) in
tumor occurrence was observed by 28 weeks in most of
the data sets analyzed (Table 5).
Discussion
Statistical methods supply the necessary procedures
to quantify the strength of the evidence in support of
the hypotheses under study. Thus, the methods used
should be intuitively reasonable and easily interpreta-
ble, with sufficient power to detect meaningful differ-
ences. The advantages and disadvantages of various
response measures and statistical methods for hypoth-
esis testing of mouse skin assay data have been ex-
amined. Traditional methods that ignore survival dif-
ferences, multiplicity of tumors, and the pattern of
tumor development may result in a loss of statistical
power. Each method has its own deficiencies. None in-
dividually are sufficient to reliably describe and test
assay data fortoxicity. For example, unadjusted tumor
incidence data should onlybe interpreted in conjunction
with an examination of the survival patterns in the
treatment groups. Methods that account for these fac-
tors eliminate biases and thus aid in ensuring the va-
lidity of the test results. Adjustment for these factors
wouldbeespeciallyimportantforlesspotentcompounds
or studies based on low doses. The exact consequence
of ignoring the potential analyses problems would de-
pend on the characteristics of the data set in question.
Response measures and methods ofanalysis were de-
rived for use in testingthe toxicity ofa compound when
survival data, tumor count data, and time oftumor oc-
currence are available. Only nonparametric and semi-
parametrictechniques were considered to eliminate the
need to specify a response distribution. The methods
developed are advantageous for several reasons. The
analyses include every animal, not just animals surviv-
ing to a given time. Tumor multiplicity is accounted for
by each ofthe response measures, and the duration and
regression oftumors are accounted forby several ofthe
univariatemethods. Themultivariate responsemeasure
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considered is the only measure examined that is not
biased by any of the characteristics of the data. It ac-
counts for mortality and time oftumor occurrence. In-
tuitively, this method seems the most reasonable; how-
ever, several assumptions are necessary to ensure its
validity. The stratified proportional hazard model as-
sumesthatthe hazard ofthe dose groups is proportional
to that ofthe control group and that tumors occur in a
single animal as a nonhomogenous Poisson process. The
model does not allow for extra variability to account for
differences in susceptibility among animals (7). Addi-
tionally, this method is computationally the most diffi-
cult, since the computer software needed for compu-
tation is not readily available.
Each of the univariate response measures has limi-
tations, and thus the analysis of the mouse skin assay
data should not be confined to one of these measures.
A thorough analysis should include an examination and
test for equality ofsurvival distributions, a comparison
oftime to first tumor distributions and a comparison of
tumormultiplicity. Each ofthese measures contains im-
portant information that should be used to interpretthe
results of an experiment. Although there were rela-
tively few cases in which the analysis of the integral
and total tumor count response measures differed, the
integral accounts for tumor duration and is thus pref-
erable to the total tumor counts as a response measure.
Thestrongperformance oftheGehan-Wilcoxonmultiple
comparisontestintheanalysis ofthe SENCARtracking
system data leads to the recommendation for its use.
As a result ofthese analyses, it can be stated that ifan
association between tumor response and dose ofa com-
pound is found and it is desirable to examine the data
for a monotone dose response, a trend analysis using
the Cox-type trend test can be performed. By con-
ducting the analysis in this manner, all available infor-
mation on the toxicity of a compound is fully used.
The research described in this paper has been peer reviewed by
the U.S. Environmental Protection Agency and approved for publi-
cation. Mention oftrade names or commercial products does not con-
stitute endorsement or recommendation for use.
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